TAG 2010 Pipeline Report

Total Page:16

File Type:pdf, Size:1020Kb

TAG 2010 Pipeline Report i-base HiV, tuberculosis, and Viral Hepatitis: drugS, diagnoStiCS, vaccineS, immune-BaSed theraPieS, and Preventive teCHNOLOGIES in develoPment TAG 2010 pipeline report july 2010 treatment action group Polly Clayden, lei Chou, Simon CollinS, mark harrington, riChard JefferyS, eleonora Jimenez, SCott morgan, traCy Swan, Javid Syed and Claire wingfield About TAG the treatment action group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. aBOUT HIV i-BaSe HIV i-Base is a london based HIV treatment activist organization. i-Base work in the UK and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included policy discussions about HIV treatment recommendations and access. i-base you can reach TAG by phone at +1.212.253.7922. to find out more about TAG’s projects go to www.treatmentactiongroup.org. treatment action group 611 Broadway, Suite 308 new york, ny 10012 tel 212.253.7922 fax 212.253.7923 [email protected] www.treatmentactiongroup.org iSBn 978-0-9819863-5-7 thiS rePort iS dediCated to vuyani Jacobs a fierce advocate for access to care and treatment for people with hiv, gender equality, and human rights. a dedicated activist, vuyani’s leadership contributed to the success of the treatment action Campaign, médicines Sans frontières, and Community health media trust. through his media work, his community organizing, and his compassion he contributed to a world where people could live free from stigma and have access to life-saving information and treatment. he died on 30 June 2010 of meningitis. table of Contents introduction & executive summary 1 the antiretroviral pipeline 7 Activity since 2008 The Pipeline in 2010 Other Compounds and targets in Preclinical research Patent expiry and generic Compounds the HiV diagnostics pipeline 25 Requirements for Point-of-Care tests The Cd4 initiative Point-of-Care viral load test the pediatric antiretroviral pipeline 29 Why not avoid Pediatric hiv in the first Place? When to Start Children on antiretroviral therapy Identifying Children with hiv and Starting them on treatment What to Start with? Dosing / formulations The innovator Pipeline The generic Pipeline the immune-based therapies and preventive technologies pipeline 44 Vaccines Vaccine approaches in human trials Preexposure Prophylaxis Immune-based therapies HIV Cure Box Hepatitis b drugs in development 70 Oral antivirals Immune-based therapies Preventive vaccine the Hepatitis c treatment pipeline 77 HCv treatment: Population-specific issues HCv treatment access Moving forward: hCv drug development Characteristics of the Class: hCv Protease inhibitors Characteristics of the Class: hCv Polymerase inhibitors Characteristics of the Class: nS5a inhibitors Nitazoxanide TAG research recommendations the tuberculosis pipeline introduction 101 the tuberculosis diagnostic pipeline 107 what is in the tB diagnostic Pipeline Health Post Peripheral laboratory Reference laboratory Immune-based tests for latent tB infection Policy and research recommendations the tuberculosis treatment pipeline 125 introduction: a robust Pipeline, but uncertain Support If tB is Curable why are new drugs needed? Accelerating research Getting Back to Basics The Pipeline So what’s new Second-generation Compounds Latent tB infection Drug Susceptible tB Rethinking last-Chance drugs Recommendations the tuberculosis Vaccine pipeline 140 BCg: the Current tB vaccine Strategy Challenges for vaccine research The tB Pipeline What is needed acknowledgments 150 introduction By mark harrington and SCott morgan For the sixth time, Treatment Action Group (TAG), now in collaboration with HIV i-Base (UK), presents the current clinical pipeline for new drugs and vaccines for HIV, hepatitis C virus (HCV), and tuberculosis (TB), along with new sections on the hepatitis B virus (HBV) pipeline and diagnostics for TB and HIV. Despite the global economic crisis and the erosion of political will to continue scal- ing up effective, lifesaving, evidence-based preventive and treatment interventions for HIV and its most common coinfections worldwide, TB, HBV and HCV, the scien- tific outlook is unexpectedly positive. Continuing growth and maturation in the HIV therapeutics market space have not yet led to a visible diminution of efforts by industry to discover and develop new antiretroviral drugs and classes. A pair of antiretroviral drugs approved in 2006 and 2007—the protease inhibitor darunavir (Prezista, Tibotec/ Johnson & Johnson) and the first-in-class integrase inhibitor raltegravir (Isentress, Merck)—joined efavirenz (EFV) and boosted atazanavir (ATV) as preferred first-line anti-HIV drugs in combination with tenofovir (TDF)/emtricitabine (3TC) (combined as Truvada) in the U.S. Department of Health & Human Services adult and adoles- cent HIV treatment guidelines published in December 2009. These advances show that there is a continued market for innovation in HIV treatment and that industry, regulators, and public health authorities agree on how best to study new drugs in order to rank them relative to existing regimens. In the coming years there may be fewer per- sons experiencing multidrug class failure to participate in earlier phase studies, which means that new trial designs will be needed; thus, the over $10 billion yearly market for HIV therapy will continue to experience dynamic changes and evolution. Five new compounds and combinations are in advanced phase III studies and expected to be filed for U.S. Food and Drug Administration (FDA) review in 2010–2011: Tibotec’s nonnucleoside reverse transcriptase inhibitor rilpivirine (TMC278); the triple combi- nation with tenofovir/3TC/rilpivirine; Gilead Science’s integrase inhibitor elvitegravir; the novel pharmacokinetic enhancer cobicstat; and the so-called Quad pill containing elvitegravir/cocibstat/tenofovir/3TC. Additional drugs in existing and new classes, the latter including maturation and attachment inhibitors, are in earlier phases of testing. The global HIV market is estimated to be growing toward over $16 billion by 2016, around the time when a wave of patent expiries will make it ever more essential for new market entries to possess qualities that are measurably superior to what will then be a much more generic sales–centered market. 1 TAG 2010 Pipeline report This year, in addition to Simon Collins’s overview of the adult HIV pipeline, Polly Clayden, also of HIV i-Base (UK), presents an update on a much-neglected area of HIV research, the pediatric antiretroviral pipeline. Shockingly, some of the most critical agents used in adult therapy, such as tenofovir, are still not available for very young infants and chil- dren; indeed, the pediatric HIV standard of care globally resembles adult HIV care about ten years ago. This must change, and Clayden’s chapter explains what will be required. In a foretaste of things to come, Clayden also provides a quick overview of global needs in HIV diagnostics, with particular focus on point-of-care diagnostic tests for early infant diagnosis, CD4 counts, and HIV RNA load. Richard Jefferys once again presents a sweeping overview of the vast areas of the HIV clinical research agenda that have yet to provide a convincing advance in either preventive or therapeutic vaccines, microbicides, immune-based therapies, cytokine treatment, or gene-/cell-based therapies, including a new section on HIV cure and eradication research. Despite the difficulties in these research areas, activity is exten- sive and the ultimate solution to the pandemic can only come from the development and worldwide distribution of an effective vaccine and a cure for HIV. The vast unmet needs in these portfolios make it even more essential to increase investments in basic and translational science over the coming years. Lei Chou’s overview of the virtual paralysis afflicting HBV research in the past year makes for much more depressing reading. There is no visible drug development for HBV in North America or Europe, with only scanty activity in east Asia, and no clinical trials from the new U.S. National Institutes of Health-funded HBV research network despite almost two years of funding. Relying exclusively on HBV vaccination for the uninfected, public health authorities seem to be consigning the fate of the hun- dreds of millions of people infected with chronic HBV infection to a very short list of effective drugs to which HBV may well develop pan-resistance before new agents are in the pipeline. The world must move beyond a vaccination-only strategy and focus on saving the lives of the many who have chronic HBV-related disease. TAG’s Hepatitis/HIV Project Director Tracy Swan has been predicting a revolution in HCV treatment since the mid-2000s. This year, her prediction has come measurably closer to reality as phase III results from trials of two HCV protease inhibitors, bocepre- vir (Merck/Schering Plough) and telaprevir, (Vertex/Tibotec) are expected by the end of 2010. Although both drugs come with added toxicity, boceprevir and telaprevir have considerable promise, offering the potential to significantly increase cure rates for the most difficult to treat genotype 1 infections, and, in some cases, to reduce treatment -du ration from 12 to 6 months. Farther back in the pipeline but even more promising are combinations of oral, direct-acting HCV antiviral compounds that
Recommended publications
  • Download Article PDF/Slides
    Kan Lu, PharmD New Antiretrovirals for Based on a presentation at prn by Roy M. Gulick, md, mph the Treatment of HIV: Kan Lu, PharmD | Drug Development Fellow University of North Carolina School of Pharmacy Chapel Hill, North Carolina The View in 2006 Roy M. Gulick, md, mph Reprinted from The prn Notebook® | october 2006 | Dr. James F. Braun, Editor-in-Chief Director, Cornell Clinical Trials Unit | Associate Professor of Medicine, Meri D. Pozo, PhD, Managing Editor. Published in New York City by the Physicians’ Research Network, Inc.® Weill Medical College of Cornell University | New York, New York John Graham Brown, Executive Director. For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©october 2006 substantial progress continues to be made in the arena of cokinetics and a long extracellular half-life of approximately 10 hours antiretroviral drug development. prn is again proud to present its annual (Zhu, 2003). During apricitabine’s development, a serious drug interac- review of the experimental agents to watch for in the coming months and tion with lamivudine (Epivir) was noted. Although the plasma years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a long- concentrations of apricitabine were unaffected by coadministration of time friend of prn, and no stranger to the antiretroviral development lamivudine, the intracellular concentrations of apricitabine were reduced pipeline. by approximately sixfold. Additionally, the 50% inhibitory concentration To date, twenty-two antiretrovirals have been approved by the Food (ic50) of apricitabine against hiv with the M184V mutation was increased and Drug Administration (fda) for the treatment of hiv infection.
    [Show full text]
  • Ep 2531027 B1
    (19) TZZ ¥_Z _T (11) EP 2 531 027 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4985 (2006.01) A61K 31/52 (2006.01) 06.05.2015 Bulletin 2015/19 A61K 31/536 (2006.01) A61K 31/513 (2006.01) A61K 38/55 (2006.01) A61P 31/18 (2006.01) (21) Application number: 11737484.3 (86) International application number: (22) Date of filing: 24.01.2011 PCT/US2011/022219 (87) International publication number: WO 2011/094150 (04.08.2011 Gazette 2011/31) (54) Therapeutic combination comprising dolutegravir, abacavir and lamivudine Therapeutische Zusammensetzung enthaltend Dolutegravir, Abacavir und Lamivudine Combinaison thérapeutique comprenant du dolutégravir, de l’abacavir et de la lamivudine (84) Designated Contracting States: (74) Representative: Gladwin, Amanda Rachel AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GlaxoSmithKline GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Global Patents (CN925.1) PL PT RO RS SE SI SK SM TR 980 Great West Road Designated Extension States: Brentford, Middlesex TW8 9GS (GB) BA ME (56) References cited: (30) Priority: 27.01.2010 US 298589 P WO-A1-2010/011812 WO-A2-2009/148600 US-A1- 2006 084 627 US-A1- 2006 084 627 (43) Date of publication of application: US-A1- 2008 076 738 US-A1- 2009 318 421 12.12.2012 Bulletin 2012/50 US-A1- 2009 318 421 US-B1- 6 544 961 (73) Proprietor: VIIV Healthcare Company • SONG1 et al: "The Effect of Ritonavir-Boosted Research Triangle Park, NC 27709 (US) ProteaseInhibitors on the HIV Integrase Inhibitor, S/GSK1349572,in Healthy Subjects", INTERNET , (72) Inventor: UNDERWOOD, Mark, Richard 15 September 2009 (2009-09-15), XP002697436, Research Triangle Park Retrieved from the Internet: URL:http: North Carolina 27709 (US) //www.natap.org/2009/ICCAC/ICCAC_ 52.htm [retrieved on 2013-05-21] Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Trends in Antiretroviral Treatment in Australia
    AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) ANNUAL REPORT (Volume 20, Number 1: December 2020) 2020 Clinical characteristics of overseas-born men who have sex with men (MSM) in the AHOD cohort and implications for clinical practice In Australia HIV notifications are increasing among overseas-born men who have sex with men (MSM), particularly among Asian-born MSM. Australian evidence suggests that culturally and/or linguistically diverse populations are less likely to start treatment early irrespective of CD4 cell count at diagnosis, but little is known about response once in care. Using data from AHOD, Jolie L Hutchinson and colleagues (2020) compared treatment response in overseas-born MSM from non-English-speaking countries with Australian-born MSM, further categorised based on participation in the Australian Temporary Residents Access Study (ATRAS) which provide temporary residents ineligible for Medicare, access to HIV treatment. ATRAS patients were chosen as the closest surrogate to identifying newly arrived overseas-born MSM. The authors explored the time to first virological suppression (VS) (viral load (VL) <400 copies/mL) and time to virological failure (VF) (>400 copies/mL after suppression). CD4 cell counts and VL measurements were taken at treatment initiation. Adjusted Hazard Ratios (HR) are reported with 95% CI. Results, as shown in figure 1, indicate that overseas-born MSM did not differ significantly in the rate of VS or in the rate of first VF after suppression. This result is different from findings in other settings, and differences may, in part, be explained by the nature of healthcare provision. In Australia, all residents can access ART for free or with a small co-payment; those ineligible for Medicare can get pharmaceutical company-provided ART which is not necessarily straightforward for non-English speakers.
    [Show full text]
  • Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Summer 8-19-2016 Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations Dhirender Singh University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Pharmaceutical Preparations Commons, and the Virus Diseases Commons Recommended Citation Singh, Dhirender, "Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations" (2016). Theses & Dissertations. 140. https://digitalcommons.unmc.edu/etd/140 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. SYNTHESIS AND DEVELOPMENT OF LONG-ACTING ABACAVIR PRODRUG NANOFORMULATIONS by Dhirender Singh A DISSERTATION Presented to the Faculty of the Graduate School in the University of Nebraska Medical Center in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Department of Pharmaceutical Science Under the Supervision of Dr. Howard E. Gendelman University of Nebraska Medical Center, Omaha, Nebraska August 2016 Supervisory Committee: Howard E. Gendelman, M.D. Ram Mahato, Ph.D JoEllyn M. McMillan, Ph.D. David Oupicky, Ph.D SYNTHESIS AND DEVELOPMENT OF LONG-ACTING ABACAVIR PRODRUG NANOFORMULATIONS Dhirender Singh, Ph.D. University of Nebraska Medical Center, 2016 Supervisor: Howard E Gendelman, M.D. Over the past decade, work from our laboratory has demonstrated the potential of targeted nanoformulated antiretroviral therapy (nanoART) to produce sustained high plasma and tissue drug concentrations for weeks following a single intramuscular (IM) administration that can suppress ongoing viral replication and mitigate dose associated viral resistance.
    [Show full text]
  • Asilo Politico in Israele
    Corso di Laurea magistrale (ordinamento ex D.M. 270/2004) in Lavoro, cittadinanza sociale, interculturalità Tesi di Laurea Asilo politico in Israele Relatore Ch. ma Prof. ssa Emanuela Trevisan Correlatore Ch. Prof. Lauso Zagato Laureanda Caterina Santin Matricola 824639 Anno Accademico 2013 / 2014 1 2 Indice generale Introduzione.........................................................................................................................................5 CAPITOLO I: Il diritto d’asilo in Israele dal 1948 al 2006.......................................................................8 1.1 Nascita dello Stato di Israele: ideologia sionista, teorie etnocentriche e concetto di Otherness.........................................................................................................................................8 1.1.1 La storia..............................................................................................................................8 1.1.2 Il movimento sionista.......................................................................................................10 1.1.3 Gli inizi dell'immigrazione ebraica...................................................................................11 1.1.4 Le teorie etnocentriche....................................................................................................13 1.1.5 We-ness e Otherness........................................................................................................16 1.2 Il sistema migratorio................................................................................................................19
    [Show full text]
  • 14-258 Phrma HIV/AIDS2014 0819.Indd
    2014 MEDICINES IN DEVELOPMENT REPORT HIV/AIDS PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention Medicines and Vaccines in Globally, approximately 35 million people effective therapies, and preventative Development for HIV Infection are infected with human immunodefi - vaccines. These medicines and vaccines ciency virus (HIV), the virus that causes are either in clinical trials or awaiting Application acquired immune defi ciency syndrome review by the U.S. Food and Drug Submitted (AIDS). However, new infections have Administration (FDA). Phase III dropped by 38 percent since 2001, Phase II The 44 medicines and vaccines in the according to UNAIDS, the Joint United Phase I development pipeline include: Nations Programme on HIV/AIDS. • A fi rst-in-class medicine intended to In the United States, more than 25 prevent HIV from breaking through 1.1 million people are living with HIV the cell membrane. and 15.8 percent of those are unaware they are infected, according to the • A cell therapy that modifi es a U.S. Centers for Disease Control and patient’s own cells in an attempt to Prevention (CDC). Although the U.S. make them resistant to HIV. HIV/AIDS-related death rate has fallen 16 by more than 80 percent since the introduction of antiretroviral therapies in Contents 1995, new HIV infections have stabilized HIV Medicines and Vaccines in at approximately 50,000 each year, Development ......................................2 according to the CDC. Incremental Innovation in HIV/AIDS Treatment .......................... 4 Since AIDS was fi rst reported in 1981, Access to HIV/AIDS Medicines in nearly 40 medicines have been approved Exchange Plans ...................................5 to treat HIV infection in the United Facts About HIV/AIDS ........................7 States.
    [Show full text]
  • Wibke E. Diederich Holger Steuber Editors Therapy of Viral Infections 15 Topics in Medicinal Chemistry
    Topics in Medicinal Chemistry 15 Wibke E. Diederich Holger Steuber Editors Therapy of Viral Infections 15 Topics in Medicinal Chemistry Editorial Board: P. R. Bernstein, Rose Valley, USA A. Buschauer, Regensburg, Germany G. I. Georg, Minneapolis, USA J. A. Lowe, Stonington, USA U. Stilz, Malov, Denmark Prof. Dr. C. T. Supuran, Sesto Fiorentino (Firenze), Italy A. K. Saxena, Lucknow, India Aims and Scope Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the new topic-related series Topics in Medicinal Chemistry will cover all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimina- tion, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors. In references Topics in Medicinal Chemistry is abbreviated Top Med Chem and is cited as a journal. More information about this series at http://www.springer.com/series/7355 Wibke E. Diederich • Holger Steuber Editors Therapy of Viral Infections With contributions by E. Bo¨ttcher-Friebertsha¨user Á U. Chiacchio Á F. Christ Á E. Crespan Á J. Demeulemeester Á Z. Debyser Á U. Dietrich Á W.E. Diederich Á R. Du¨rr Á F.G.R. Ehlert Á C. Frezza Á A. Garbelli Á W. Garten Á S.V. Giofre` Á K. Hardes Á M.
    [Show full text]
  • Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS)
    Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Update on 2004 Background Paper Written by Warren Kaplan Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS) By Warren Kaplan, Ph.D., JD, MPH 15 February 2013 Update on 2004 Background Paper, BP 6.7 HIV/AIDS Table of Contents What is new since 2004? ..................................................................................................................................... 4 1. Introduction ................................................................................................................................................. 7 2. What are the Epidemiological Trends for Europe and the World? ................................................... 7 2.1 Western and Central Europe ............................................................................................................. 7 2.2 Eastern Europe .................................................................................................................................... 9 2.2 The World (including Europe) ........................................................................................................ 11 3. What is the Control Strategy? Is There an Effective Package of Control Methods Assembled into a “Control Strategy” for Most Epidemiological Settings?................................................................. 13 3.1 Is there a pharmaceutical ‘gap’? ....................................................................................................
    [Show full text]
  • Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
    Viruses 2010, 2, 606-638; doi:10.3390/v2020606 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase Kamalendra Singh, Bruno Marchand, Karen A. Kirby, Eleftherios Michailidis and Stefan G. Sarafianos * Christopher Bond Life Sciences Center & Department of Molecular Microbiology & Immunology, University of Missouri, Columbia, Missouri 65211, USA; E-Mails: [email protected] (K.S.); [email protected] (B.M.); [email protected] (K.A.K.); [email protected] (E.M.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-573-882-4338. Received: 2 December 2009; in revised form: 22 January 2010 / Accepted: 3 February 2010 / Published: 11 February 2010 Abstract: HIV-1 Reverse Transcriptase (HIV-1 RT) has been the target of numerous approved anti-AIDS drugs that are key components of Highly Active Anti-Retroviral Therapies (HAART). It remains the target of extensive structural studies that continue unabated for almost twenty years. The crystal structures of wild-type or drug-resistant mutant HIV RTs in the unliganded form or in complex with substrates and/or drugs have offered valuable glimpses into the enzyme’s folding and its interactions with DNA and dNTP substrates, as well as with nucleos(t)ide reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTIs) drugs. These studies have been used to interpret a large body of biochemical results and have paved the way for innovative biochemical experiments designed to elucidate the mechanisms of catalysis and drug inhibition of polymerase and RNase H functions of RT.
    [Show full text]
  • Shai Yehezkelli Cv
    SHAI YEHEZKELLI CV EDUCATION 2010 Master of Fine Arts with honors at the Bezalel Academy of Art & Design, Tel-Aviv, Israel 2006 Bachelor of Fine Arts, Summa Cum Laude, at the Bezalel Academy of Art & Design, Jerusalem, Israel SELECTED SOLO EXHIBITIONS 2019 "The Great Sieste”, Chelouche gallery, Tel-Aviv "Maarava", Mindy Solomon gallery, Miami 2018 "Heel To Toe", Oded Shatil Contemporary Art Space, Tel-Aviv "Nothing Went Wrong to Write Home About", 2025 Kunst und Kultur, Hamburg 2016 "In Praise of Avalanche", The 2015 Rappaport Prize for a Young Israeli Artist, Tel Aviv Museum of Art (Curator: Anat Danon-Sivan) 2014 "With Philistines", Julie M. Gallery, Tel Aviv 2012 "Forever Sweat-Beads", Julie M. Gallery, Tel Aviv "Space C", Haifa museum of Art 2009 “Shouldn’t Couldn’t Wouldn’t“, Darom, Tel Aviv (Curator: Eden Bannet) 2007 “Fountain”, Solo gallery, Tel Aviv (Curator: Dana Taggar) SELECTED TWO-PERSON EXHIBITIONS 2019 "Support Beam Fall" With Eden Bannet, Villa Gallery, Jerusalem (Curator: Alfa Haimov) 2014 “Abigail Hopkins . Shai Yehezkelli", Ha'Kibbutz Gallery, Tel Aviv (Curator: Yael Keyni) 2013 "Depression Delights" with Sharon Fadida, The New & Bad gallery, Haifa (Curator: Natalie Levin) 2007 “Chay Tseeyurim” With Ran Keydar, Barbur, Jerusalem (Curators: Avi Sabah, Masha Zusman, Yanai Segal) SELECTED GROUP EXHIBITIONS Mindy Solomon Gallery [email protected] 8397 NE 2nd Avenue mindysolomon.com Miami, FL 33138 P 786-953-6917 United States F 786-464-0240 SHAI YEHEZKELLI CV 2019 “Hidden Hour”, Mindy Solomon Gallery, Miami, Florida "Maarbolot", Chelouche Gallery, Tel-Aviv 2018 "Stav", Maya Gallery, Tel-Aviv (Curator: Tsibi Geva) “No Other Place - Decade Exhibition”, The Tel Aviv Convention Center, Fresh Paint art fair “The Origin of Who U Are Right Now”, Kvadrat16 gallery, Copenhagen "Between Walls", Binyamin Gallery, Tel-Aviv (Curator: Gal Attia) "Weiße Weste", Il Caminetto, Hamburg (Curator: Rebekka Seubert) 2017 "There Will Be Nothing", MFA Gallery of Bezalel Academy, Tel-Aviv (Curators: Yitzhak Livneh, Dor Guez) “Art after Chagall.
    [Show full text]
  • 2013 Prioritisation Report Priority Antiretrovirals for the Medicines
    PRIORITY ANTIRETROVIRALS FOR THE MEDICINES PATENT POOL Third Edition | December 2013 Advancing innovation, access, and public health 1 CONTENTS 3 Introduction 4 Section 1: ARV Prioritisation in Light of New WHO Treatment Guidelines 5 Priority Regimens for Adults 9 Priority Regimens for Children and Adolescents 13 Section 2: Prioritisation of New ARVs and ARVs in the Pipeline 16 Conclusions 18 Annex I - Methodology 22 Annex II - Product Cards 23 Annex IIa: Product Cards for ARVs Prioritised in Light of New WHO Treatment Guidelines 36 Annex IIb: Product Cards for New ARVs and ARVs in the Pipeline 45 Annex IIc: Products in Early Stages of Development* 48 Annex III - Acronyms and Definitions 51 References ACKNOWLEDGMENTS The lead authors of this Working Paper were Esteban Burrone, Head of Policy, and Fernando Pascual, Medical/Pharmaceutical Consultant, of the Medicines Patent Pool. The paper also benefitted from extensive inputs from Robyn Harshaw, Sandeep Juneja, Kaitlin Mara, Chan Park, and Greg Perry. The Medicines Patent Pool (MPP) wants to thank the following external peer reviewers for their comments on an earlier draft: Jintanat Ananworanich, Pascale Boulet, Pedro Cahn, Polly Clayden, Jennifer Cohn, Meg Doherty, Diane Gibb, Raul Gonzalez, Andy Gray, Andrew Hill, Janice Lee, Rohit Malpani, Carmen Pérez-Casas, David Ripin, Marco Vitoria, and the MPP Expert Advisory Group composed of: Labeeb Abboud, Jonathan Berger, Alexandra Calmy, Shing Chang, Carlos Correa, Nelson Juma Otwoma, Eun-Joo Min, Lita Nelsen, Achal Prabhala, Gracia Violeta Ross, Maximiliano Santa Cruz, and Wim Vandevelde. 2 INTRODUCTION TO THE THIRD EDITION OF THE WORKING PAPER Since the first antiretroviral (ARV) information on the patent status, regulatory status received regulatory approval by the US and market trends for different ARVs.
    [Show full text]
  • Antiviral Drugs in the Treatment of Aids: What Is in the Pipeline ?
    October 15, 2007 EU RO PE AN JOUR NAL OF MED I CAL RE SEARCH 483 Eur J Med Res (2007) 12: 483-495 © I. Holzapfel Publishers 2007 ANTIVIRAL DRUGS IN THE TREATMENT OF AIDS: WHAT IS IN THE PIPELINE ? Hans-Jürgen Stellbrink Infektionsmedizinisches Centrum Hamburg ICH, Hamburg, Germany Abstract even targeting immune responses have to be devel- Drug development in the field of HIV treatment is oped. Continued drug development serves the ulti- rapid. New nucleoside analogues (NRTI), non-nucleo- mate goal of normalization of life expectancy. side analogue reverse transcriptase inhibitors (NNR- TI), and protease inhibitors (PI) are currently being in- METHODS vestigated in human trials. Furthermore, inhibitors of HIV attachment, fusion and integrase with novel Drug development in the field of HIV infection is modes of action are being developed, which offer new highly competitive, and a company’s decision to pur- perspectives for the goal of a normalization of life-ex- sue or discontinue the development of a drug is dri- pectancy in HIV-infected individuals. The most ad- ven by economic rather than scientific considerations. vanced compounds likely to become licensed soon in- Of all candidate compounds, only a few reach the lev- clude the NNRTIs rilpivirine and etravirine, the inte- el of trials in humans, and some exhibit lack of effica- grase inhibitors raltegravir and elvitegravir, and mar- cy or toxicity problems at this stage. Some compounds aviroc and vicriviroc, novel inhibitors of the CCR5 also have no obvious advantage over currently avail- chemokine receptor, which functions as the major able ones, so that their development is discontinued.
    [Show full text]